Targeted treatment matching and better trial access for gynecologic cancers
Official title: Gynecologic cancer care: Improving clinical trial enrollment through molecular matching with targeted therapies and improving access to care and research
Funded at Ohio State University · NIH-11191381 · Data updated 2026-11-12
This project helps people with gynecologic cancers get matched to targeted medicines based on their tumor's molecular profile and makes clinical trials easier to join.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | September 11, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $132,015 |
| NIH project number | 5R50CA287196-02 |
| Project ID | NIH-11191381 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are people with gynecologic cancers—especially endometrial or other uterine cancers—with molecular testing results or who are willing to have their tumor tested for actionable mutations or mismatch repair status.
✕Less likely to help
Patients without targetable molecular changes, those not eligible for the linked clinical trials, or people with non-gynecologic cancers are unlikely to benefit directly from this effort.
What this research studies
You would benefit from a program that checks tumor DNA and other molecular features to find targeted therapies or trials that fit your cancer. The team at Ohio State will build a system to match patients to molecularly driven clinical trials and improve how patients are referred and enrolled. They will work with their comprehensive cancer center resources and with partners nationally to reach more people, including underrepresented groups. The goal is faster, fairer access to trials and therapies guided by each patient’s tumor biology.
Why it matters
Potential benefit: If successful, more patients could receive treatments matched to their tumor type, avoid ineffective therapies, and have better chances of improved outcomes.
How similar studies have gone: Molecular matching and targeted therapy trials have shown promise in gynecologic and other cancers (for example, immunotherapy benefit in mismatch repair–deficient tumors), but enrollment barriers remain and this project focuses on improving access.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Backes, Floor J. — Ohio State University
- Study coordinator: Backes, Floor J.
Related research
Other NIH-funded projects on the same topics.
-
Standardized, patient-centered treatment plans for breast and gynecologic cancer survivors facing sexual dysfunction and vaginal microbiome changes
A patient-friendly program tests personalized, non-hormonal treatment plans for sexual dysfunction in breast cancer survivors, guided by changes in the vaginal microbiome.
-
Gynecologic cancer care: faster enrollment in targeted trials through molecular matching and better access to care
Aims to speed up enrollment in personalized gynecologic cancer trials by matching patients to targeted therapies and improving access to care.
-
WNT4 and gynecologic cancer: a genetic link to therapy resistance and disparities
Researchers are studying how a gene variant called WNT4 may influence gynecologic cancers and contribute to differences in risk among populations, with the aim of improving future treatments.
-
Virtual Mindful After Cancer program to improve sexual health for breast and gynecologic cancer survivors
A web-based mindfulness program is being tested to help breast and gynecologic cancer survivors who have sexual health concerns.
-
Promoting open talks about sexual health after gynecologic cancer
A patient-focused program helps women with gynecologic cancer start and guide conversations about sexual health with their doctors.
-
Modernizing Gynecologic Cancer Trial Rules to Enroll More Patients
Aims to make gynecologic cancer clinical trials more accessible to diverse patients so more people can benefit from new treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.